MMP9 and anaphylaxis: In this study, we identified four approved drugs that have the potential to be repurposed against hub genes involved in anaphylaxis complicated STEMI, including anakinra, baclofen, andecaliximab, and albuterol targeting IL1R2, FOS, MMP9, and DUSP1, respectively.